Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical everolimus versus placebo for facial angiofibromas in tuberous sclerosis complex
2018-002531-18Phase 2Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in facial angiofibroma and tuberous sclerosis complex (TSC) comparing Topical everolimus with Placebo (2 arms). Started Jul 2018; status: active.
02
Drugs
everolimus
03
Conditions
facial angiofibromatuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on 2018-002531-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002531-18.